Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis.
Infection with Trichinella spiralis in mice was accompanied by allergic sensitization as evidenced by anaphylactic death after intravenous injection of the antigen. Pre-treatment of the animals with oxatomide, a new orally active anti-allergic drug, resulted in significant protection of the animals; the lowest effective dose of the compound was 1.25 mg/kg orally. In contrast to cyproheptadine, oxatomide offered little protection against serotonin toxicity in mice. The present data suggest that, in this model of systemic hypersensitivity, the anti-anaphylactic effect of oxatomide can be attributed mainly to inhibition of release of allergic mediators.
D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D008297:Male; D051379:Mice; D010879:Piperazines / Q000494:pharmacology*; D012701:Serotonin / Q000633:toxicity; D012702:Serotonin Antagonists; D014235:Trichinellosis / Q000276:immunology* / Q000503:physiopathology
D010879:Piperazines; D012702:Serotonin Antagonists; D012701:Serotonin; C015408:oxatomide